Pharmaceuticals

Drug Development Biotechnology Drug Pricing Manufacturing Acquisitions Drug Manufacturing Vaccine Development Market Competition Mergers and Acquisitions Corporate Governance

Pfizer-Valneva Lyme Vaccine Shows 70% Efficacy but Misses Primary Goal

Regulators now face a strong efficacy signal paired with a primary-endpoint miss.

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Stories older than 24h

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

Eton Pharma Launches FDA-Approved Desmota as Revenue and Margins Jump

Collegium to Acquire AZSTARYS for $650 Million, Adding Second ADHD Medicine

Roche Expands NVIDIA Partnership, Building Pharma’s Largest Hybrid‑Cloud AI Factory

Artelo Secures Fully Funded Investigator-Led Glaucoma Trial With Belfast Health Trust

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Roche Launches Nvidia-Powered AI Factory With 2,176 New Blackwell GPUs, Claims Pharma’s Largest Footprint

FDA Expands GSK’s Arexvy to High-Risk Adults 18–49, Completing Trio of RSV Vaccines for Younger At‑Risk Group

Eli Lilly to Invest $3 Billion in China to Build Orforglipron Manufacturing

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

ANI Pharmaceuticals Posts Record Quarter as Rare-Disease Drugs Power 29.6% Sales Jump

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

Novartis to Build 46,000‑Square‑Foot Radioligand Therapy Plant in Denton, Texas

AbbVie to Invest $380 Million in Two North Chicago API Plants

Astellas–Vir Prostate Cancer Alliance Launches With New Data as VIR Stock Surges